Zolmitriptan is Effective for the Treatment of Persistent and Recurrent Migraine Headache

References

• Schoenen J., Sawyer J. Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)1. Schoenen J., Sawyer J. Zolmitriptan (ZomigTM, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)
   PubMed Web of Science ®Google Scholar
• Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997; 49: 1210–12182. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997; 49: 1210–1218
   PubMed Web of Science ®Google Scholar
• Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 1997; 49: 1219–12253. Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 1997; 49: 1219–1225
   PubMed Web of Science ®Google Scholar
• Tepper S., Donnan G. A., Dowson A. J., Bomhof M. A. M., Elkind A., Meloche J., Fletcher P. E., Millson D. S. A long-term study to maximize migraine relief with Zolmitriptan. Curr. Med. Res. Opin. 1999; 15(4)254–2714. Tepper S., Donnan G. A., Dowson A. J., Bomhof M. A. M., Elkind A., Meloche J., Fletcher P. E., Millson D. S. A long-term study to maximize migraine relief with Zolmitriptan. Curr. Med. Res. Opin. 1999; 15(4)254–271
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)5. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)
   Web of Science ®Google Scholar
• Visser W. H., Jaspers N. M., De Vriend R. H., Ferrari M. D. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554–5596. Visser W. H., Jaspers N. M., De Vriend R. H., Ferrari M. D. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554–559
   PubMed Web of Science ®Google Scholar
• Mathew N. T. Serotonin 1D (5-HTID) agonists and other agents in acute migraine. Neurol. Clin. 1997; 15(1)61–837. Mathew N. T. Serotonin 1D (5-HTID) agonists and other agents in acute migraine. Neurol. Clin. 1997; 15(1)61–83
   PubMed Web of Science ®Google Scholar
• International 311C90 Long-Tern Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig™, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38: 173–1838. International 311C90 Long-Tern Study Group. The long-term tolerability and efficacy of oral zolmitriptan (ZomigTM, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38: 173–183
   PubMed Web of Science ®Google Scholar
• Edmeads J. G., Millson D. S. Tolerability profile of zolmitriptan (Zomig™; 311C90), a novel dual central and peripherally acting 5HTIB/ID agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia 1997; 17: 41–52, (Suppl 18)9. Edmeads J. G., Millson D. S. Tolerability profile of zolmitriptan (ZomigTM; 311C90), a novel dual central and peripherally acting 5HTIB/ID agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia 1997; 17: 41–52, (Suppl 18)
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V., Cunin G., Sjonell G., Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg. 50 mg and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184–19010. Pfaffenrath V., Cunin G., Sjonell G., Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg. 50 mg and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184–190
   PubMed Web of Science ®Google Scholar
• Cull R. E., Price W. H., Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J. Neural. Neurosurg. Psychiatry 1997; 62: 490–49511. Cull R. E., Price W. H., Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J. Neural. Neurosurg. Psychiatry 1997; 62: 490–495
   PubMed Web of Science ®Google Scholar